Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease

Authors: Lee Campbell, Ghaith Al-Jayyoussi, Robert Gutteridge, Nigel Gumbleton, Rosie Griffiths, Simon Gumbleton, Mathew W Smith, David FR Griffiths, Mark Gumbleton

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

Up to 40% of patients initially diagnosed with clinically-confined renal cell carcinoma (RCC) and who undergo curative surgery will nevertheless relapse with metastatic disease (mRCC) associated with poor long term survival. The discovery of novel prognostic/predictive biomarkers and drug targets is needed and in this context the aim of the current study was to investigate a putative caveolin-1/ERK signalling axis in clinically confined RCC, and to examine in a panel of RCC cell lines the effects of caveolin-1 (Cav-1) on pathological processes (invasion and growth) and select signalling pathways.

Methods

Using immunohistochemistry we assessed the expression of both Cav-1 and phosphorylated-ERK (pERK) in 176 patients with clinically confined RCC, their correlation with histological parameters and their impact upon disease-free survival. Using a panel of RCC cell lines we explored the functional effects of Cav-1 knockdown upon cell growth, cell invasion and VEGF-A secretion, as well Cav-1 regulation by cognate cell signalling pathways.

Results

We found a significant correlation (P = 0.03) between Cav-1 and pERK in a cohort of patients with clinically confined disease which represented a prognostic biomarker combination (HR = 4.2) that effectively stratified patients into low, intermediate and high risk groups with respect to relapse, even if the patients’ tumours displayed low grade and/or low stage disease. In RCC cell lines Cav-1 knockdown unequivocally reduced cell invasive capacity while also displaying both pro-and anti-proliferative effects; targeted knockdown of Cav-1 also partially suppressed VEGF-A secretion in VHL-negative RCC cells. The actions of Cav-1 in the RCC cell lines appeared independent of both ERK and AKT/mTOR signalling pathways.

Conclusion

The combined expression of Cav-1 and pERK serves as an independent biomarker signature with potential merit in RCC surveillance strategies able to predict those patients with clinically confined disease who will eventually relapse. In a panel of in-vitro RCC cells Cav-1 promotes cell invasion with variable effects on cell growth and VEGF-A secretion. Cav-1 has potential as a therapeutic target for the prevention and treatment of mRCC.
Appendix
Available only for authorised users
Literature
1.
Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, Brasaemle DL, Scherer PE, Lisanti MP: Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes. 2004, 53: 1261-1270. 10.2337/diabetes.53.5.1261.CrossRefPubMed
2.
Williams TM, Lisanti MP: The Caveolin genes: from cell biology to medicine. Ann Med. 2004, 36: 584-595. 10.1080/07853890410018899.CrossRefPubMed
3.
Pike LJ: Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta. 2005, 1746: 260-273. 10.1016/j.bbamcr.2005.05.005.CrossRefPubMed
4.
Burgermeister E, Liscovitch M, Rocken C, Schmid RM, Ebert MP: Caveats of caveolin-1 in cancer progression. Cancer Lett. 2008, 268: 187-201. 10.1016/j.canlet.2008.03.055.CrossRefPubMed
5.
Goetz JG, Lajoie P, Wiseman SM, Nabi IR: Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008, 27: 715-735. 10.1007/s10555-008-9160-9.CrossRefPubMed
6.
Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA: Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. Neoplasia. 2008, 10: 140-148. 10.1593/neo.07817.PubMedCentralCrossRefPubMed
7.
Li L, Ren CH, Tahir SA, Ren C, Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003, 23: 9389-9404. 10.1128/MCB.23.24.9389-9404.2003.PubMedCentralCrossRefPubMed
8.
Arpaia E, Blaser H, Quintela-Fandino M, Duncan G, Leong HS, Ablack A, Nambiar SC, Lind EF, Silvester J, Fleming CK: The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene. 2012, 31: 884-896. 10.1038/onc.2011.288.PubMedCentralCrossRefPubMed
9.
Rossi S, Poliani PL, Cominelli M, Bozzato A, Vescovi R, Monti E, Fanzani A: Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma. Eur J Cancer. 2011, 47: 761-772. 10.1016/j.ejca.2010.10.018.CrossRefPubMed
10.
Corn PG, Thompson TC: Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res. 2010, 2: 111-122.PubMedCentralCrossRefPubMed
11.
Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D: Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res. 2011, 71: 832-841. 10.1158/0008-5472.CAN-10-0730.PubMedCentralCrossRefPubMed
12.
Podar K, Anderson KC: Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett. 2006, 233: 10-15. 10.1016/j.canlet.2005.02.035.CrossRefPubMed
13.
Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, Powe D, Reis-Filho JS, Ellis IO: Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer. 2008, 99: 327-334. 10.1038/sj.bjc.6604463.PubMedCentralCrossRefPubMed
14.
Sagara Y, Mimori K, Yoshinaga K, Tanaka F, Nishida K, Ohno S, Inoue H, Mori M: Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer. 2004, 91: 959-965.PubMedCentralPubMed
15.
Bender FC, Reymond MA, Bron C, Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 2000, 60: 5870-5878.PubMed
16.
Fine SW, Lisanti MP, Galbiati F, Li M: Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol. 2001, 115: 719-724. 10.1309/YL54-CCU7-4V0P-FDUT.CrossRefPubMed
17.
Chen HL, Fan LF, Gao J, Ouyang JP, Zhang YX: Differential expression and function of the caveolin-1 gene in non-small cell lung carcinoma. Oncol Rep. 2011, 25: 359-366.PubMed
18.
Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J: Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun. 1999, 255: 580-586. 10.1006/bbrc.1999.0236.CrossRefPubMed
19.
Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, Chung DH: Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer. 2003, 42: 195-202. 10.1016/S0169-5002(03)00287-3.CrossRefPubMed
20.
Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC: Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010, 183: 1309-1315. 10.1016/j.juro.2009.12.035.CrossRefPubMed
21.
Lam JS, Leppert JT, Belldegrun AS, Figlin RA: Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005, 23: 202-212. 10.1007/s00345-004-0466-0.CrossRefPubMed
22.
Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008, 34: 193-205. 10.1016/j.ctrv.2007.12.001.CrossRefPubMed
23.
Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI: Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011, 60: 644-661. 10.1016/j.eururo.2011.06.041.CrossRefPubMed
24.
Campbell L, Gumbleton M, Griffiths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer. 2003, 89: 1909-1913. 10.1038/sj.bjc.6601359.PubMedCentralCrossRefPubMed
25.
Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M: Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol. 2004, 172: 718-722. 10.1097/01.ju.0000130943.23317.08.CrossRefPubMed
26.
Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ: Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 2004, 93: 291-296. 10.1111/j.1464-410X.2004.04604.x.CrossRefPubMed
27.
Campbell L, Nuttall R, Griffiths D, Gumbleton M: Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer. 2009, 115: 3457-3467. 10.1002/cncr.24389.CrossRefPubMed
28.
Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF: Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer. 2008, 98: 931-940. 10.1038/sj.bjc.6604243.PubMedCentralCrossRefPubMed
29.
Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M: Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010, 119: 575-591. 10.1007/s10549-009-0355-8.CrossRefPubMed
30.
Thomas DH, Verghese A, Kynaston HG, Griffiths DF: Analysis of the prognostic implications of different tumour margin types in renal cell carcinoma. Histopathology. 2003, 43: 374-380. 10.1046/j.1365-2559.2003.01721.x.CrossRefPubMed
31.
Wang Y, Roche O, Xu C, Moriyama EH, Heir P, Chung J, Roos FC, Chen Y, Finak G, Milosevic M: Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc Natl Acad Sci U S A. 2012, 109: 4892-4897. 10.1073/pnas.1112129109.PubMedCentralCrossRefPubMed
32.
Aubert S, Fauquette V, Hemon B, Lepoivre R, Briez N, Bernard D, van Seuningen I, Leroy X, Perrais M: MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 2009, 69: 5707-5715. 10.1158/0008-5472.CAN-08-4905.CrossRefPubMed
33.
Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, Krieg A, Bedogni B, LaGory E, Weissman IL: VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci USA. 2011, 108: 1931-1936. 10.1073/pnas.1011777108.PubMedCentralCrossRefPubMed
34.
Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y: Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol. 2009, 218: 530-539. 10.1002/path.2567.CrossRefPubMed
35.
Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ: Surveillance for renal cell carcinoma: why and how? When and how often?. Urol Oncol. 2008, 26: 550-554. 10.1016/j.urolonc.2007.05.026.CrossRefPubMed
36.
Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007, 5: 379-385. 10.3816/CGC.2007.n.020.CrossRefPubMed
37.
Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G: Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer. 2009, 115: 3651-3660. 10.1002/cncr.24438.CrossRefPubMed
38.
Park J, Bae E, Lee C, Yoon SS, Chae YS, Ahn KS, Won NH: RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol. 2010, 31: 643-650. 10.1007/s13277-010-0081-1.CrossRefPubMed
39.
Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa M, Enokida H: microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol. 2013, 190: 1059-1068. 10.1016/j.juro.2013.02.089.CrossRefPubMed
40.
Tringali C, Lupo B, Silvestri I, Papini N, Anastasia L, Tettamanti G, Venerando B: The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling beta1 integrin internalization and recycling. J Biol Chem. 2012, 287: 42835-42845. 10.1074/jbc.M112.407718.PubMedCentralCrossRefPubMed
41.
42.
Evdokimova V, Tognon C, Ng T, Sorensen PH: Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle. 2009, 8: 2901-2906. 10.4161/cc.8.18.9537.CrossRefPubMed
43.
Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH: Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009, 15: 402-415. 10.1016/j.ccr.2009.03.017.CrossRefPubMed
44.
Draberova E, Vinopal S, Morfini G, Liu PS, Sladkova V, Sulimenko T, Burns MR, Solowska J, Kulandaivel K, de Chadarevian JP: Microtubule-severing ATPase spastin in glioblastoma: increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation. J Neuropathol Exp Neurol. 2011, 70: 811-826.PubMedCentralCrossRefPubMed
45.
Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW: The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 2010, 16: 3628-3638. 10.1158/1078-0432.CCR-09-3022.PubMedCentralCrossRefPubMed
46.
Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003, 63: 917-926. 10.1046/j.1523-1755.2003.00805.x.CrossRefPubMed
47.
Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC: Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res. 2009, 7: 1781-1791. 10.1158/1541-7786.MCR-09-0255.CrossRefPubMed
48.
Kofman AE, McGraw MR, Payne CJ: Rapamycin increases oxidative stress response gene expression in adult stem cells. Aging (Albany NY). 2012, 4: 279-289.
49.
Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H: PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol. 2008, 28: 3281-3289. 10.1128/MCB.00310-08.PubMedCentralCrossRefPubMed
50.
Dasari A, Bartholomew JN, Volonte D, Galbiati F: Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res. 2006, 66: 10805-10814. 10.1158/0008-5472.CAN-06-1236.PubMedCentralCrossRefPubMed
Metadata
Title
Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease
Authors
Lee Campbell
Ghaith Al-Jayyoussi
Robert Gutteridge
Nigel Gumbleton
Rosie Griffiths
Simon Gumbleton
Mathew W Smith
David FR Griffiths
Mark Gumbleton
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-255

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue

Research

Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy

Research

Preserved endothelial function in human obesity in the absence of insulin resistance

Research

Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival

Research

A Lectin-EGF antibody promotes regulatory T cells and attenuates nephrotoxic nephritis via DC-SIGN on dendritic cells

Research

Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation

Methodology

Implementation of the CDC translational informatics platform - from genetic variants to the national Swedish Rheumatology Quality Register
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits